IBD Outcomes

Our focus on performing epidemiological and outcomes research in inflammatory bowel diseases (IBD) is motivated by a desire to better understand the factors that drive favorable or unfavorable clinical outcomes in IBD.

Several avenues of active investigation include the following domains:

• Value-based care delivery and quality improvement
• Assessment of the impact of different diagnostic and therapeutic algorithms in IBD
• Identification and testing of novel therapies

Related publications

• Valle NP, Roney AR, Noorian S, Greb AC, Weber AT, Sauk JS, Kwaan MR, Limketkai BN. The impact of perioperative immunosuppression on post-surgical outcomes in patients with inflammatory bowel disease. Dig Dis Sci 2026
• Chang A, Shahrvini B, Oh J, Prajapati DP, Baniqued M, Harmon R, Greb AC, Bonthala N, Sauk JS, Shin A, Chang L, Limketkai BN. Increased autoimmunity burden is a risk factor for developing irritable bowel syndrome-like symptoms in quiescent inflammatory bowel disease. Dig Dis Sci 2026;71(6):2340-6
• Tripathi K, Godoy-Brewer G, Thu Nguyen M, Singh Y, Saleh Ismail M, Sauk JS, Parian AM, Limketkai BN. COVID-19 and outcomes in patients with inflammatory bowel disease: Systematic review and meta-analysis. Inflamm Bowel Dis 2022;28(8):1265-79
• Lowe SC, Sauk JS, Limketkai BN, Kwaan MR. Declining rates of surgery for inflammatory bowel disease in the era of biologic therapy. J Gastrointest Surg 2021;25(1):211-9
• Noorian S, Jeon Y, Nguyen MT, Sauk J, Limketkai BN. The impact of NAFLD on hospitalization outcomes in patients with inflammatory bowel diseases: nationwide analysis. Inflamm Bowel Dis 2021